Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX2008 Phase 1 in Healthy Adults
NCT05761431Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SYHX2008 in acromegaly (6 cohorts), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Incidence and severity of adverse events up to 60 days. Started Mar 2023; status: completed.
02
Drugs
SYHX2008
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT05761431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761431.